Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy

被引:7
作者
Watters, JW
McLeod, HL
机构
[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA
关键词
genetics; genomics; mouse; pharmacogenetics; pharmacology;
D O I
10.1517/14622416.3.6.781
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacogenomics seeks to understand the genetic basis of interindividual differences in drug disposition and effects. Differential drug response is likely to most often be a complex trait, in which multiple genes contribute with varying strengths to the therapeutic phenotype. Due to technical and economic limitations, pharmacogenomic studies in humans are mainly limited to a small number of candidate genes with relatively major influences on drug response. This review discusses the problems involved in mapping genes underlying drug response in humans and highlights the theoretical and applied uses of mouse genetics to address these important issues.
引用
收藏
页码:781 / 790
页数:10
相关论文
共 89 条
[51]   Overview of QTL mapping software and introduction to map manager QT [J].
Manly, KF ;
Olson, JM .
MAMMALIAN GENOME, 1999, 10 (04) :327-334
[52]   Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing [J].
Martinez, FD ;
Graves, PE ;
Baldini, M ;
Solomon, S ;
Erickson, R .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3184-3188
[53]   The use of single-nucleotide polymorphism maps in pharmacogenomics [J].
McCarthy, JJ ;
Hilfiker, R .
NATURE BIOTECHNOLOGY, 2000, 18 (05) :505-508
[54]   POLYMORPHIC THIOPURINE METHYLTRANSFERASE IN ERYTHROCYTES IS INDICATIVE OF ACTIVITY IN LEUKEMIC BLASTS FROM CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
MCLEOD, HL ;
RELLING, MV ;
LIU, Q ;
PUI, CH ;
EVANS, WE .
BLOOD, 1995, 85 (07) :1897-1902
[55]   Pharmacogenomics: Unlocking the human genome for better drug therapy [J].
McLeod, HL ;
Evans, WE .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :101-121
[56]  
MILLER AM, 1978, EXP HEMATOL, V6, P455
[57]   The roads from phenotypic variation to gene discovery: mutagenesis versus QTLs [J].
Nadeau, JH ;
Frankel, WN .
NATURE GENETICS, 2000, 25 (04) :381-384
[58]   Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? [J].
Nebert, DW .
CLINICAL GENETICS, 1999, 56 (04) :247-258
[59]   Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics [J].
Nebert, DW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 410 (2-3) :107-120
[60]   Genetic linkage analysis of susceptibility to particle exposure in mice [J].
Ohtsuka, Y ;
Brunson, KJ ;
Jedlicka, AE ;
Mitzner, W ;
Clarke, RW ;
Zhang, LY ;
Eleff, SM ;
Kleeberger, SR .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2000, 22 (05) :574-581